Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.375
+$0.055 · +1.66%
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Regular session
$3.375
+$0.055 · +1.66%
Regular session · ET · Market data may be delayed.
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Day range
Current $3.375
52-week range
Current $3.375
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
21
Expensive
Sentiment
53
Mixed
Risk
59
Elevated Risk
Momentum
58
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Day range
Current $3.375
52-week range
Current $3.375
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 31.37M USD | 43.27M USD | 46.02M USD | 41.4M USD | 36.94M USD |
| Cost of goods sold | 2.07M USD | 3.71M USD | 4.63M USD | 8.33M USD | 8.18M USD |
| Gross profit | 29.31M USD | 39.56M USD | 41.39M USD | 33.08M USD | 28.76M USD |
| Research and development | 221.04M USD | 132.93M USD | 64.66M USD | 49.64M USD | 28.5M USD |
| Selling, general, and administrative | 51.7M USD | 52.49M USD | 51.79M USD | 60.32M USD | 53.08M USD |
| Operating expenses | 272.74M USD | 185.42M USD | 116.45M USD | 132.72M USD | 84.04M USD |
| Interest income | 11.75M USD | 15.09M USD | 6.95M USD | 2.13M USD | 292K USD |
| Interest expense | — | 14K USD | 1.25M USD | 3.19M USD | 5.5M USD |
| Depreciation and amortization | 2.31M USD | 1.54M USD | 464K USD | 2.45M USD | 2.77M USD |
| Operating income | −243.43M USD | −145.85M USD | −75.07M USD | −99.64M USD | −55.28M USD |
| Net income | −231.96M USD | −130.87M USD | −70.8M USD | −102.25M USD | −58.42M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI11.9M0.00%2.3T USD0.03%$379.54-0.39%
iShares Russell 2000 ETFIWM6.84M0.01%78.56B USD0.19%$274.73-1.07%
Vanguard Extended Market ETFVXF4.12M0.00%95.4B USD0.05%$231.28-0.95%
State Street SPDR S&P Pharmaceuticals ETFXPH3.46M0.71%462.1M USD0.35%$62.495-0.66%
iShares Russell 2000 Growth ETFIWO2.03M0.01%14.25B USD0.24%$350.44-1.39%
Vanguard Russell 2000 ETFVTWO2M0.01%18B USD0.06%$110.97-1.11%
Schwab U.S. Small-Cap ETFSCHA1.45M0.01%21.7B USD0.03%$32.285-1.00%
Dimensional - US Small Cap ETFDFAS1.34M0.00%33.66B USD0.31%$77.345-0.74%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
